Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial
暂无分享,去创建一个
Akshay S. Desai | S. Solomon | M. Pfeffer | A. Desai | J. McMurray | B. Brenner | H. Parving | S. Haffner | N. Chaturvedi | T. Ninomiya | D. de Zeeuw | H. Heerspink | D. Zeeuw | F. Persson | S. Haffner | P. Brunel | S. Solomon | A. Desai | S. M. Haffner | P. Brunel
[1] R. Gansevoort,et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. , 2014, Annals of internal medicine.
[2] D. de Zeeuw,et al. Microalbuminuria: target for renoprotective therapy PRO. , 2014, Kidney international.
[3] H. Parving,et al. Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors , 2014, Diabetes Care.
[4] Paul Shekelle,et al. Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.
[5] F. Wolf,et al. Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.
[6] Paul Shekelle,et al. Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.
[7] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[8] J. Chan,et al. Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] S. Bangalore,et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials , 2013, BMJ.
[10] H. Mischak,et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus , 2013, Diabetologia.
[11] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[12] D. de Zeeuw,et al. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] T. Berl,et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. , 2011, European heart journal.
[14] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[15] Mark Woodward,et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.
[16] Stian Lydersen,et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. , 2009, Journal of the American Society of Nephrology : JASN.
[17] S. Solomon,et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] D. de Zeeuw,et al. Screening for albuminuria identifies individuals at increased renal risk. , 2009, Journal of the American Society of Nephrology : JASN.
[19] P. Colville-Nash,et al. The role played by endocytosis in albumin-induced secretion of TGF-beta1 by proximal tubular epithelial cells. , 2007, American journal of physiology. Renal physiology.
[20] B. Brenner,et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. , 2007, Journal of the American Society of Nephrology : JASN.
[21] G. Bakris,et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.
[22] E. Lewis,et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[24] B. Brenner,et al. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.
[25] Zhongxin Zhang,et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.
[26] K. Borch-Johnsen,et al. Albuminuria reflects widespread vascular damage , 1989, Diabetologia.
[27] M. Nieminen,et al. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.
[28] G. Remuzzi,et al. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.
[29] Hans L Hillege,et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.
[30] H. Parving,et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.
[31] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[32] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[33] H Birn,et al. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. , 2001, American journal of physiology. Renal physiology.
[34] G. Remuzzi,et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. , 1998, Kidney international.
[35] G. Remuzzi,et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.